Literature DB >> 18974634

Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes.

R Latagliata1, E N Oliva, P Volpicelli, I Carmosino, M Breccia, I Vincelli, C Alati, L Napoleone, F Vozella, F Nobile, G Alimena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18974634     DOI： 10.1159/000166864

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  4 in total

Review 1.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  Thomy Tonia; Annette Mettler; Nadège Robert; Guido Schwarzer; Jerome Seidenfeld; Olaf Weingart; Chris Hyde; Andreas Engert; Julia Bohlius
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 2.  Treatment of low-risk myelodysplastic syndromes.

Authors:  Valeria Santini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

3.  The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study.

Authors:  Muzeyyen Aslaner Ak; Birsen Sahip; Ayfer Geduk; Mehmer Ali Ucar; Hacer Kale; Tugba Hacibekiroglu; Merve Gokcen Polat; Yasin Kalpakci; Ali Zahit Bolaman; Birol Guvenc; Sehmus Ertop
Journal:  Indian J Hematol Blood Transfus       Date:  2021-06-26       Impact factor: 0.900

4.  Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.

Authors:  Enrico Balleari; Rosa Angela Filiberti; Chiara Salvetti; Bernardino Allione; Emanuele Angelucci; Marco Bruzzone; Tullio Calzamiglia; Marina Cavaliere; Maurizio Cavalleri; Daniela Cilloni; Marino Clavio; Elena Crisà; Anna Da Col; Paolo Danise; Federica Pilo; Dario Ferrero; Carlo Finelli; Daniela Gioia; Roberto Massimo Lemoli; Elisa Masiera; Emanuela Messa; Maurizio Miglino; Pellegrino Musto; Esther Natalie Oliva; Antonella Poloni; Flavia Salvi; Alessandro Sanna; Marco Scudeletti; Rodolfo Tassara; Valeria Santini
Journal:  Cancer Med       Date:  2019-10-27       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.